CANCER CYTOGENETICS

Indications for Cancer Cytogenetics:

  • Leukemias
  • Lymphomas
  • Solid tumors

Applications of Cancer Cytogenetics:

  • Establish the presence of a malignant clone and clarify the diagnosis.
  • Confirm and characterize hematological disorders.
  • Stage the disease progress.
  • Monitor course of treatment of leukemia and lymphoma.
  • Indicate a prognosis.
  • Assist with the choice of a treatment strategy.
  • Confirm remission or relapse.
  • Support further research.


Deviations from the normal chromosomal number, including hyperploids or structural changes, are detectable in more than 95% of leukemia’s and various tumors, some being recognised as well known to be associated with certain stages and types of Neoplasia with various clinical consequences.

FISH test for cancer samples uses a wide range of DNA fluorescence in-situ probes in order to (1) identify the chromosomal small rearrangements associated with specific hematopoietic disorders and solid tumors, (2) monitor course of treatment of leukemia and lymphoma, (3) confirm remission or relapse in hematopoietic disorders, and (4) indicate prognosis and adjunct to histological diagnosis of solid tumors.

Structural chromosomal aberrations indicate the cancer phase and can predict the prognosis, helping the clinician to choose the right treatment protocol.

 

Disease- specific FISH panels are available for:

Acute Lymphocytic Leukemia (ALL)

  • Multiprobe
  • cMYC  Breakapart
  • E2A  Break apart
  • P16  deletion
  • TEL/AML1
  • BCR/ABL dual fusion
  • MLL Breakapart
  • IGH Breakapart
  • Hyperdiploidy

Acute Myeloid Leukemia(AML) / Myelodysplastic Syndrome (MDS)

  • Del (5q)
  • PML/RARAα Translocation Dual Fusion
  • P53
  • AML1/ETO Translocation dual fusion
  • Trisomy  8
  • MLL Breakapart
  • Del (7q)
  • CBFβ/MY 11 Translocation Dual Fusion
  • Del (20q) (MYBL2)

Chronic Myelogenous Leukemia Probe

  • BCR/ABL   Plus Translocation Dual Fusion

 

Disease-specific FISH panels available on request in consultation with pathologists:

Chronic Lymphocytic/Small Lymphocytic Leukemia

  • MYB  Deletion
  • ATM Deletion
  • Chromosome 12 Enumeration
  • IGH/BCL2 Translocation
  • IGH/CCND1 (BCL1) Translocation
  • IGH Breakapart
  • P53 Deletion
  • 13q4.3 Deletion

◊Lymphomas

  • IGH/BCL2 Dual Fusion Translocation
  • IGH/CCND1 XT Dual Fusion Translocation
  • IGH/MYC/CEP 8 Tri colour DF.

◊Breast Cancer

  • Breast Aneusomy Multi colour probe
  • EGFR / CEP 7
  • CCND1 / CEP 11
  • C MYC
  • TOP2A/ HER-2/ CEP 17
  • ZNF 217

◊Sarcomas

  • EWSR1 Break Apart 22q12

◊Neuroblastoma

  • N- MYC2p24
  • BCL 6 (ABR) Dual Color, Break Apart 3q27

◊Retinoblastoma

  • RB1 deletion



Counseling and informed consent are recommended for genetic testing.